Breast Cancer Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Breast Cancer Therapy Market is Segmented by Therapy (Radiation Therapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts in Terms of Value (USD Million) for the Above Segments.

Breast Cancer Therapy Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Breast Cancer Therapy Market Size

Breast Cancer Therapy Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Market Size (2025) USD 32.90 Billion
Market Size (2030) USD 46.51 Billion
CAGR (2025 - 2030) 7.17 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

Breast Cancer Therapy Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Breast Cancer Therapy Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Breast Cancer Therapy Market Analysis

The Breast Cancer Therapy Market size is estimated at USD 32.90 billion in 2025, and is expected to reach USD 46.51 billion by 2030, at a CAGR of 7.17% during the forecast period (2025-2030).

The major factors fueling the market's growth are the high incidence and prevalence rates of breast cancer, increasing investment in research and development, and advancements in cancer biology and pharmacology, promoting drug development.

According to Globocan, in 2020, about 2,261,419 new cancer cases were reported worldwide, contributing to about 11.7% of the total cancer cases. As per canceraustralia.gov.au, in 2021, 20,030 new breast cancer cases were diagnosed in the country (164 males and 19,866 females). The same source reports that in 2021, a person had an estimated 1 in 15 (or 6.7%) risk of being diagnosed with breast cancer by the age of 85 (1 in 8 or 13% for females and 1 in 829 or 0.12% for males). Therefore, the high burden of breast cancer is increasing the demand for breast cancer treatment, thereby contributing to the market's growth.

The increasing focus of research studies by the market players. For instance, in September 2021, Novartis AS collaborated with Solti on HARMONIA, an international, randomized, Phase III, multicenter, and open-label study of Kisqali (ribociclib) versus Ibrance (palbociclib), both in combination with endocrine therapy. This study was on patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer with a HER2-enriched (HER2E) intrinsic subtype.

Increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive market growth. For instance, in July 2021, Arvinas Inc. and Pfizer Inc. collaborated to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. Such factors potentially drive the demand for the adoption of breast cancer therapy worldwide.

On the other hand, the risk of adverse effects of radiation exposure and stringent regulatory scenarios are hindering the market's growth.

Breast Cancer Therapy Industry Overview

The breast cancer therapy market is competitive and consists of several major and small players. Some of the major players in the market are Novartis AG, Pfizer Inc., F. Hoffmann-La Roche, Eisai Co. Ltd., and Merck & Co. Inc.

Breast Cancer Therapy Market Leaders

  1. Novartis AG

  2. Merck Co & Inc.

  3. Fresenius Kabi

  4. Pfizer Inc.

  5. Eli Lilly & Co.

  6. *Disclaimer: Major Players sorted in no particular order
Breast Cancer Therapy Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Breast Cancer Therapy Market News

  • In September 2022, Novartis announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer (aBC).
  • In August 2022, the United States Food and Drug Administration approved Enhertu (fam-trastuzumab-deruxtecan-nxki), an IV infusion for the treatment of patients with unresectable (unable to be removed) or metastatic (spread to other parts of the body) HER2-low breast cancer. This is one of the first approved therapies targeted to patients with the HER2-low breast cancer subtype, which is a newly defined subset of HER2-negative breast cancer.

Breast Cancer Therapy Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 High Incidence and Prevalence Rate of Breast Cancer
    • 4.2.2 Increasing Investments in R&D
    • 4.2.3 Advancements in Cancer Biology and Pharmacology, Promoting Drug Development
  • 4.3 Market Restraints
    • 4.3.1 Risk of Adverse Effects of Radiation Exposure
    • 4.3.2 Stringent Regulatory Scenarios
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Suppliers
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Therapy
    • 5.1.1 Radiation Therapy
    • 5.1.2 Targeted Therapy
    • 5.1.2.1 Herceptin
    • 5.1.2.2 Tykerb (Lapatinib)
    • 5.1.2.3 Afinitor
    • 5.1.2.4 Other Targeted Therapies
    • 5.1.3 Hormonal Therapy
    • 5.1.3.1 Selective Estrogen - Receptor Modulators
    • 5.1.3.2 Aromatase Inhibitors
    • 5.1.3.3 Other Hormonal Therapies
    • 5.1.4 Chemotherapy
    • 5.1.4.1 Taxanes
    • 5.1.4.2 Anthracyclines
    • 5.1.4.3 Anti-metabolites
    • 5.1.4.4 Alkylating Agents
    • 5.1.4.5 Epothilones
  • 5.2 Geography
    • 5.2.1 North America
    • 5.2.1.1 United States
    • 5.2.1.2 Canada
    • 5.2.1.3 Mexico
    • 5.2.2 Europe
    • 5.2.2.1 Germany
    • 5.2.2.2 United Kingdom
    • 5.2.2.3 France
    • 5.2.2.4 Italy
    • 5.2.2.5 Spain
    • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
    • 5.2.3.1 China
    • 5.2.3.2 Japan
    • 5.2.3.3 India
    • 5.2.3.4 Australia
    • 5.2.3.5 South Korea
    • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle East and Africa
    • 5.2.4.1 GCC
    • 5.2.4.2 South Africa
    • 5.2.4.3 Rest of Middle East and Africa
    • 5.2.5 South America
    • 5.2.5.1 Brazil
    • 5.2.5.2 Argentina
    • 5.2.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AstraZeneca PLC
    • 6.1.2 Bristol-Myers Squibb Company
    • 6.1.3 Eisai Co. Ltd
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Genentech
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Halozyme Inc.
    • 6.1.8 Novartis AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Hikma Pharmaceuticals
    • 6.1.11 Baxter Healthcare Corporation
    • 6.1.12 FRESENIUS KABI
    • 6.1.13 Teva Pharmaceutical Industries Ltd
    • 6.1.14 Celltrion Healthcare
    • 6.1.15 Viatris Inc.
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Breast Cancer Therapy Industry Segmentation

As per the scope of this report, breast cancer therapy refers to cancer treatment with chemotherapy, targeted therapy, hormonal therapy, etc. These therapies block the growth and proliferation of cancer by interfering with specific molecules, such as DNA or proteins, that are involved in the growth or expansion of cancerous cells. The breast cancer therapy market is segmented by therapy (radiation therapy, targeted therapy, hormonal therapy, and chemotherapy) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the market sizes and forecasts in terms of value (USD million) for the above segments.

By Therapy Radiation Therapy
Targeted Therapy Herceptin
Tykerb (Lapatinib)
Afinitor
Other Targeted Therapies
Hormonal Therapy Selective Estrogen - Receptor Modulators
Aromatase Inhibitors
Other Hormonal Therapies
Chemotherapy Taxanes
Anthracyclines
Anti-metabolites
Alkylating Agents
Epothilones
Geography North America United States
Canada
Mexico
Geography Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Geography Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Geography Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
Geography South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Breast Cancer Therapy Market Research FAQs

How big is the Breast Cancer Therapy Market?

The Breast Cancer Therapy Market size is expected to reach USD 32.90 billion in 2025 and grow at a CAGR of 7.17% to reach USD 46.51 billion by 2030.

What is the current Breast Cancer Therapy Market size?

In 2025, the Breast Cancer Therapy Market size is expected to reach USD 32.90 billion.

Who are the key players in Breast Cancer Therapy Market?

Novartis AG, Merck Co & Inc., Fresenius Kabi, Pfizer Inc. and Eli Lilly & Co. are the major companies operating in the Breast Cancer Therapy Market.

Which is the fastest growing region in Breast Cancer Therapy Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Breast Cancer Therapy Market?

In 2025, the North America accounts for the largest market share in Breast Cancer Therapy Market.

What years does this Breast Cancer Therapy Market cover, and what was the market size in 2024?

In 2024, the Breast Cancer Therapy Market size was estimated at USD 30.54 billion. The report covers the Breast Cancer Therapy Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Breast Cancer Therapy Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Breast Cancer Therapy Industry Report

Statistics for the 2025 Breast Cancer Therapy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Breast Cancer Therapy analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.